April 17, 2020
Multicenter SOLSTICE Study Evaluates Targeted Interventional Cryoablation of Metastatic Lung Tumors
April 17, 2020—The investigators in the SOLSTICE study concluded that percutaneous cryoablation is a safe and effective treatment for pulmonary metastases. Matthew R. Callstrom, MD, et al published the findings online ahead of print in the Journal of Thoracic Oncology.
To assess the safety and local recurrence-free survival in patients after cryoablation for treatment of pulmonary metastases, the multicenter, prospective, single-arm, phase 2 SOLSTICE study enrolled 128 patients with 224 lung metastases treated with percutaneous cryoablation. Key inclusion criteria included one to six metastases from extrapulmonary cancers with a maximal diameter of 3.5 cm.
As summarized in Journal of Thoracic Oncology, time to progression of the index tumor(s), metastatic disease, and overall survival rates were estimated using the Kaplan-Meier method. Complications were captured for 30 days after the procedure, and changes in performance status and quality of life were also evaluated. Follow-up was conducted at 12 and 24 months.
The median size of metastases was 1 ± 0.6 cm (0.2–4.5), with a median number of tumors of 1 ± 1.2 (1–6).
In Journal of Thoracic Oncology, the investigators reported the following for local tumor efficacy:
- Local recurrence-free response of the treated tumor was 172 of 202 (85.1%) at 12 months and 139 of 180 (77.2%) at 24 months after the initial treatment.
- Secondary local recurrence-free response was 184 of 202 (91.1%) at 12 months and 152 of 180 (84.4%) at 24 months after a second cryoablation treatment for recurrent tumor
Additionally, the study found:
- Overall survival rates were 97.6% (95% confidence interval [CI], 92.6–99.2) at 12 months and 86.6% (95% CI, 78.7–91.7) at 24 months.
- The rate of pneumothorax that required pleural catheter placement was 26% (44/169).
- There were eight (4.7%) grade 3 complication events and one (0.6%) grade 4 event in 169 procedures.